ENOB Insider Trading Activity and SEC Form 4 Filings
ENOB insider trading summary
No open-market insider purchases or sales of Enochian Biosciences Inc (ENOB) have been reported on SEC Form 4 in the past 12 months.
Latest ENOB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 18, 2022 | Rene Sindlev | Director | Buy | $1.0M (125,000 @ $8.00) |
| May 18, 2022 | Rene Sindlev | Director | Buy | $1.0M (128,493 @ $8.00) |
| May 18, 2022 | Serhat Gumrukcu | 10% Owner | Sell | $1.0M (125,000 @ $8.00) |
| May 18, 2022 | Serhat Gumrukcu | 10% Owner | Sell | $1.0M (128,493 @ $8.00) |
| Mar 22, 2022 | Carl Forest Sandler | Director | Sell | $17K (1,927 @ $9.06) |
| Feb 23, 2022 | Carl Forest Sandler | Director | Sell | $54 (6 @ $9.00) |
| Feb 18, 2022 | Carl Forest Sandler | Director | Sell | $61K (6,792 @ $9.03) |
| Jun 4, 2019 | Rene Sindlev | Director | Buy | $211K (31,500 @ $6.70) |
| Jun 3, 2019 | Rene Sindlev | Director | Buy | $268K (40,000 @ $6.70) |
| May 29, 2019 | Rene Sindlev | Director | Buy | $132K (20,000 @ $6.60) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.